Vertex Pharmaceuticals (VRTX) Change in Account Payables (2009 - 2026)

Vertex Pharmaceuticals' Change in Account Payables history runs 18 years deep, the most recent figure standing at $35.6 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 35.88% year-over-year to $35.6 million; the TTM figure through Mar 2026 stood at $46.2 million (down 38.89% YoY), while the FY2025 annual figure was $36.8 million, down 25.66% from the prior year.
• Change in Account Payables was $35.6 million for Q1 2026 at Vertex Pharmaceuticals, down from $38.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $159.9 million in Q4 2022 to a low of -$69.9 million in Q3 2022.
• Historically, Change in Account Payables has averaged $17.1 million across 5 years, with a median of $9.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables plunged 3139.13% in 2022, then soared 26100.0% in 2025.
• A 5-year view of Change in Account Payables shows it stood at $159.9 million in 2022, then plunged by 119.89% to -$31.8 million in 2023, then surged by 126.42% to $8.4 million in 2024, then jumped by 355.95% to $38.3 million in 2025, then decreased by 7.05% to $35.6 million in 2026.
• The last three Change in Account Payables figures came in at $35.6 million (Q1 2026), $38.3 million (Q4 2025), and -$35.3 million (Q3 2025), per Business Quant data.